CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
other
OA: closed
public-domain-us
AI-generated summary
This review summarizes the aberrant expression and involvement of long non-coding RNA CDKN2B-AS1 in various malignancies and non-malignant diseases, highlighting its potential as a therapeutic target or prognostic biomarker.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: In view of the roles of long non-coding RNA CDKN2B antisense RNA 1 (CDKN2BAS1) in various human diseases, we investigated the function of CDKN2B-AS1 and explored its therapeutic and prognostic target value in multiple biological processes. The aim of this review was to explore the molecular mechanism and clinical significance of CDKN2B-AS1 in various types of diseases.
MATERIALS AND METHODS: In this review, the biological functions and mechanisms of lncRNA CDKN2B-AS1 in a variety of pathophysiological processes were summarized and analyzed. The correlated studies were collected via a systematic search of PubMed, Wiley Online Library, and ScienceDirect.
RESULTS: CDKN2B-AS1 is a potential long non-coding RNA that has been shown to be aberrantly expressed in various malignancies, containing hepatocellular carcinoma, intrahepatic cholangiocarcinoma, esophageal squamous cell carcinoma, gastric cancer, colonic adenocarcinoma, cervical cancer, ovarian cancer, breast cancer, glioma, lung cancer, laryngeal squamous cell carcinoma and osteosarcoma, involving in the processes of tumor cells proliferation, migration, invasion and inhibition of tumor cells apoptosis. Besides, CDKN2B-AS1 has been proved implicated in numerous non-malignant diseases, such as idiopathic pulmonary fibrosis, endometriosis, inflammatory bowel disease, intracranial aneurysm, diabetes mellitus and its complications, primary open angle glaucoma, ischemic stroke, atherosclerosis, coronary artery diseases, hypertension and heart failure, participating in the procession of lipid, carbohydrate metabolism and inflammation regulation.
CONCLUSION: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases.
Full text
7,442 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Abstract
Background: In view of the roles of long non-coding RNA CDKN2B antisense RNA 1 (CDKN2BAS1) in various human diseases, we investigated the function of CDKN2B-AS1 and explored its therapeutic and prognostic target value in multiple biological processes. The aim of this review was to explore the molecular mechanism and clinical significance of CDKN2B-AS1 in various types of diseases.
Materials and methods
In this review, the biological functions and mechanisms of lncRNA CDKN2B-AS1 in a variety of pathophysiological processes were summarized and analyzed. The correlated studies were collected via a systematic search of PubMed, Wiley Online Library, and ScienceDirect.
Results
CDKN2B-AS1 is a potential long non-coding RNA that has been shown to be aberrantly expressed in various malignancies, containing hepatocellular carcinoma, intrahepatic cholangiocarcinoma, esophageal squamous cell carcinoma, gastric cancer, colonic adenocarcinoma, cervical cancer, ovarian cancer, breast cancer, glioma, lung cancer, laryngeal squamous cell carcinoma and osteosarcoma, involving in the processes of tumor cells proliferation, migration, invasion and inhibition of tumor cells apoptosis. Besides, CDKN2B-AS1 has been proved implicated in numerous non-malignant diseases, such as idiopathic pulmonary fibrosis, endometriosis, inflammatory bowel disease, intracranial aneurysm, diabetes mellitus and its complications, primary open angle glaucoma, ischemic stroke, atherosclerosis, coronary artery diseases, hypertension and heart failure, participating in the procession of lipid, carbohydrate metabolism and inflammation regulation.
Conclusion
Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases.
Keywords
LncRNAs, CDKN2B-AS1, tumor, non-malignant diseases, malignancies, prognosis biomarker.
[http://dx.doi.org/10.1016/j.ceb.2013.08.005] [PMID: 24529241]
[http://dx.doi.org/10.1371/journal.pone.0033389] [PMID: 22428042]
[PMID: 31646789]
[http://dx.doi.org/10.1002/cam4.1541] [PMID: 29761859]
[http://dx.doi.org/10.1016/j.canlet.2018.08.024] [PMID: 30165194]
[http://dx.doi.org/10.1002/hep.29890] [PMID: 29572888]
[http://dx.doi.org/10.1038/nrclinonc.2017.157] [PMID: 28994423]
[http://dx.doi.org/10.1016/j.dld.2019.03.019] [PMID: 31040073]
[PMID: 28401021]
[http://dx.doi.org/10.1111/cas.14447] [PMID: 32378752]
[http://dx.doi.org/10.1111/cas.13130] [PMID: 27960044]
[http://dx.doi.org/10.1007/s13277-016-4808-5] [PMID: 26753962]
[http://dx.doi.org/10.1097/CAD.0000000000000216] [PMID: 25646744]
[http://dx.doi.org/10.1111/apt.12814] [PMID: 24912650]
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[http://dx.doi.org/10.1016/j.cgh.2019.07.045] [PMID: 31362118]
[http://dx.doi.org/10.1002/jcb.28520] [PMID: 30834580]
[http://dx.doi.org/10.18632/oncotarget.6926] [PMID: 26788991]
[http://dx.doi.org/10.1093/carcin/bgu203] [PMID: 25239644]
[http://dx.doi.org/10.18632/oncotarget.1902] [PMID: 24810364]
[http://dx.doi.org/10.1177/1535370219860207] [PMID: 31242038]
[http://dx.doi.org/10.1002/iub.1490] [PMID: 27027260]
[http://dx.doi.org/10.1038/s41598-019-52883-2] [PMID: 31729423]
[http://dx.doi.org/10.1002/jcb.27697] [PMID: 30269368]
[PMID: 26408699]
[http://dx.doi.org/10.1016/j.biopha.2016.11.058] [PMID: 27899255]
[http://dx.doi.org/10.3727/096504017X14953948675449] [PMID: 28550682]
[http://dx.doi.org/10.1002/cam4.2040] [PMID: 30884187]
[http://dx.doi.org/10.18632/oncotarget.8744] [PMID: 27095571]
[http://dx.doi.org/10.3892/ijo.2015.2943] [PMID: 25845387]
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2980] [PMID: 27197191]
[http://dx.doi.org/10.4149/neo_2020_190617N515] [PMID: 32305052]
[http://dx.doi.org/10.1016/j.bbrc.2019.03.141] [PMID: 31014670]
[http://dx.doi.org/10.1007/s40471-017-0115-y] [PMID: 29226065]
[http://dx.doi.org/10.1016/S0140-6736(16)31891-8] [PMID: 27865536]
[http://dx.doi.org/10.1111/febs.13352] [PMID: 26094658]
[http://dx.doi.org/10.1038/s41598-018-31859-8] [PMID: 30323354]
[http://dx.doi.org/10.1016/j.ncrna.2016.09.002] [PMID: 30159409]
[http://dx.doi.org/10.1158/1541-7786.MCR-15-0418] [PMID: 27102007]
[http://dx.doi.org/10.1007/s13277-015-4135-2] [PMID: 26409453]
[http://dx.doi.org/10.1097/MD.0000000000006222] [PMID: 28248879]
[http://dx.doi.org/10.1177/117822341000400004] [PMID: 20697531]
[http://dx.doi.org/10.1016/j.biopha.2017.09.107] [PMID: 28961506]
[http://dx.doi.org/10.1158/1055-9965.EPI-18-1026] [PMID: 31040135]
[http://dx.doi.org/10.1371/journal.pone.0163067] [PMID: 27780202]
[http://dx.doi.org/10.1158/1055-9965.EPI-14-1106] [PMID: 25713050]
[http://dx.doi.org/10.1186/s40246-019-0240-4] [PMID: 31775885]
[http://dx.doi.org/10.1002/1878-0261.12188] [PMID: 29504701]
[http://dx.doi.org/10.1007/s12094-019-02134-7] [PMID: 31172444]
[PMID: 27307748]
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0492] [PMID: 25504755]
[http://dx.doi.org/10.18632/oncotarget.18512] [PMID: 28881680]
[PMID: 30555745]
[http://dx.doi.org/10.2147/OTT.S221620] [PMID: 31754305]
[http://dx.doi.org/10.1177/1724600819898489] [PMID: 31960744]
[http://dx.doi.org/10.1089/cbr.2019.2885] [PMID: 31724892]
[http://dx.doi.org/10.1007/s11626-019-00415-7] [PMID: 31950433]
[http://dx.doi.org/10.1186/s12931-017-0581-2] [PMID: 28521775]
[http://dx.doi.org/10.3892/ol.2018.7910] [PMID: 29541247]
[http://dx.doi.org/10.5603/GP.a2018.0052] [PMID: 30010178]
[http://dx.doi.org/10.1017/thg.2015.61] [PMID: 26337243]
[http://dx.doi.org/10.1093/humupd/dmu015] [PMID: 24676469]
[http://dx.doi.org/10.1111/jgh.14031] [PMID: 29063720]
[http://dx.doi.org/10.1016/j.dld.2017.08.003] [PMID: 28869157]
[http://dx.doi.org/10.1016/j.lfs.2019.116571] [PMID: 31207308]
[http://dx.doi.org/10.1097/MIB.0000000000000691] [PMID: 26937624]
[http://dx.doi.org/10.1016/j.bbrc.2018.11.100] [PMID: 30477744]
[http://dx.doi.org/10.1016/j.amjms.2018.10.016] [PMID: 30665494]
[http://dx.doi.org/10.3349/ymj.2019.60.7.651] [PMID: 31250579]
[PMID: 27188739]
[http://dx.doi.org/10.3171/2019.4.FOCUS19204] [PMID: 31261114]
[http://dx.doi.org/10.1007/s00125-016-4132-z] [PMID: 27744525]
[http://dx.doi.org/10.1152/ajpendo.00268.2017] [PMID: 29118015]
[http://dx.doi.org/10.1016/j.biopha.2019.109622] [PMID: 31707340]
[http://dx.doi.org/10.1007/s00417-019-04409-9] [PMID: 31327036]
[http://dx.doi.org/10.1371/journal.pone.0186678] [PMID: 29261660]
[http://dx.doi.org/10.1016/j.ophtha.2012.02.004] [PMID: 22521085]
[http://dx.doi.org/10.1093/hmg/ddv128] [PMID: 25861811]
[http://dx.doi.org/10.1007/s11239-018-01802-9] [PMID: 30656483]
[http://dx.doi.org/10.1016/j.gene.2019.01.041] [PMID: 30738964]
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.020] [PMID: 29773352]
[http://dx.doi.org/10.1096/fj.201802252R] [PMID: 30870006]
[http://dx.doi.org/10.18087/cardio.2018.8.10160] [PMID: 30131040]
[http://dx.doi.org/10.1097/MOL.0b013e3283654e7c] [PMID: 24005217]
[http://dx.doi.org/10.1074/jbc.RA118.005050] [PMID: 30655286]
[http://dx.doi.org/10.1038/nature09753] [PMID: 21307941]
[PMID: 28287809]
[http://dx.doi.org/10.1002/mgg3.955] [PMID: 31496134]
[http://dx.doi.org/10.14744/AnatolJCardiol.2018.90907] [PMID: 30587704]
[http://dx.doi.org/10.1111/jcmm.13790] [PMID: 30079603]
[http://dx.doi.org/10.1016/j.clinbiochem.2016.02.012] [PMID: 26944720]
[http://dx.doi.org/10.1089/gtmb.2017.0249] [PMID: 29791233]
[http://dx.doi.org/10.1371/journal.pgen.1003588] [PMID: 23861667]
[http://dx.doi.org/10.1186/s12967-016-0926-5] [PMID: 27317124]
[PMID: 30586722]
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-01T06:12:48.306406+00:00
- pubmed
- last seen: 2026-05-13T22:21:47.975235+00:00
- unpaywall
- last seen: 2026-09-01T06:29:04.589233+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine